BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
February 27, 2024 15:52 ET | BioAegis Therapeutics
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
HelixBind_Logo_AS2-no BG (2018).png
Study Demonstrates the Potential of HelixBind’s RaPID/BSI Assay to Accurately Identify Bloodstream Infections Associated with Sepsis in Patients Undergoing Antimicrobial Treatment
February 12, 2024 08:30 ET | HelixBind
Study shows RaPID/BSI assay can accurately identify bloodstream infections associated with sepsis in patients undergoing antimicrobial treatment.
Research Nester Logo.jpg
Pancreatic Stone Protein Testing Market revenue to reach USD 5 Billion by 2033, says Research Nester
February 07, 2024 07:30 ET | Research Nester
New York, Feb. 07, 2024 (GLOBE NEWSWIRE) -- The global pancreatic stone protein testing market size is predicted to grow at a CAGR of over ~3% from 2023 to 2033. The market is projected to garner a...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
October 16, 2023 14:40 ET | BioAegis Therapeutics
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Oct....
adrenomed-logo (002).jpg
Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update
September 08, 2023 04:00 ET | Adrenomed AG
Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented todayIn the AdrenOSS-2 trial, the respective patient...
Logo 400x400.jpg
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
September 01, 2023 16:43 ET | CytoSorbents
PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
Logo 400x400.jpg
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
August 31, 2023 07:00 ET | CytoSorbents
PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...
Our Lady of the Lake
Our Lady of the Lake Health First in Nation to Implement Life-Saving Sepsis Detection Technology
August 02, 2023 10:10 ET | Franciscan Missionaries of Our Lady Health System
Baton Rouge, LA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- A first-of-its-kind, life-saving diagnostic tool that detects sepsis in patients in under 10 minutes is now in use at Our Lady of the Lake Regional...
Logo.png
Sepsis Market Size and Share to Grow by 2032, Examines DelveInsight | Key Companies Developing Therapies - Regeneron, Merck, Shionogi, Sentien Biotechnologies, Basilea, Vivacelle Bio, Sanofi, BioAegis, Pharmazz
June 29, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, June 29, 2023 (GLOBE NEWSWIRE) -- Sepsis Market Size and Share to Grow by 2032, Examines DelveInsight | Key Companies Developing Therapies - Regeneron, Merck, Shionogi, Sentien...
FBI LOGO TM.png
With 9.7% CAGR, Sepsis Diagnostics Market Size to Reach USD 1,603.3 Million by 2030
April 17, 2023 07:09 ET | Fortune Business Insights
Pune, India, April 17, 2023 (GLOBE NEWSWIRE) -- The global sepsis diagnostics market size was valued at USD 770.4 million in 2022. The market is projected to grow from USD 840.5 million in 2023 to...